SCHEMBL26127649

SCHEMBL26127649

CN(C(=O)OCC1c2ccccc2-c2ccccc21)C(CC(=O)O)C(=O)O

nearest known ligand 0.47

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ CASP3 P42574 4/20 0.47
▸ CYP1A2 P05177 1/20 0.45
▸ TSHR P16473 1/20 0.45
▸ KMT2A Q03164 2/20 0.44
▸ FABP5 Q01469 3/20 0.43
▸ FABP7 O15540 2/20 0.43
▸ PTGIR P43119 1/20 0.40
▸ EPHX2 P34913 1/20 0.39
▸ MDM4 O15151 1/20 0.39
▸ TP53 P04637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29416526 1.00 CASP3 (0.47) CASP3CYP1A2TSHRKMT2AFABP5
SCHEMBL26010080 1.00 CASP3 (0.47) CASP3CYP1A2TSHRKMT2AFABP5
SCHEMBL29696633 0.91 CASP3 (0.49) CASP3CYP1A2TSHRKMT2AFABP5
SCHEMBL24633569 0.91 CASP3 (0.49) CASP3CYP1A2TSHRKMT2AFABP5
SCHEMBL29697687 0.91 CASP3 (0.49) CASP3CYP1A2TSHRKMT2AFABP5
SCHEMBL23879119 0.91 CASP3 (0.49) CASP3CYP1A2TSHRKMT2AFABP5
SCHEMBL24579191 0.91 CASP3 (0.49) CASP3CYP1A2TSHRKMT2AFABP5
SCHEMBL30896052 0.91 CASP3 (0.49) CASP3CYP1A2TSHRKMT2AFABP5
SCHEMBL31129066 0.91 CASP3 (0.43) CASP3CYP1A2TSHRKMT2AFABP5
SCHEMBL29696769 0.90 CASP3 (0.41) CASP3CYP1A2TSHRKMT2AFABP5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114478701-B Heptapeptide with anti-tumor activity, and preparation method and application thereof 广西民族大学 2024-04-19 — — CN disclosed
WO-2023195516-A1 PRODUCTION METHOD FOR PEPTIDE COMPOUND 中外製薬株式会社 2023-10-12 — — WO disclosed
EP-2906246-B1 VEGF NEUTRALIZING PRODRUGS COMPRISING RANIBIZUMAB FOR THE TREATMENT OF OCULAR CONDITIONS CHARACTERIZED BY OCULAR NEOVASCULARIZATION ASCENDIS PHARMA OPHTHALMOLOGY DIV A/S (DK) 2023-07-26 — — EP disclosed
CN-114478701-A Heptapeptide with anti-tumor activity and preparation method and application thereof 广西民族大学 2022-05-13 — — CN disclosed
CN-113692401-A Process for producing aromatic amino acid derivative 中外制药株式会社 2021-11-23 — — CN disclosed
CN-104755103-A VEGF neutralizing prodrugs for the treatment of ocular conditions ASCENDIS PHARMA OPHTHALMOLOGY DIVISION AS 2015-07-01 — — CN disclosed
Send feedback